Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Minimal Hepatic Encephalopathy
Interventions
rifaximin
Drug
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Richmond, Virginia
Completed Phase 2 Interventional Results available

Blood Lipopolysaccharide (LPS) Rifaximin Study

NCT02124512
Conditions
Obese, Insulin Resistance, Metabolic Syndrome
Interventions
Rifaximin SSD, Placebo
Drug · Other
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Liver Cirrhosis, Renal Failure
Interventions
Rifaximin, Lactulose
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea
Interventions
Rifaximin, Glucose and lactulose hydrogen breath testing
Drug · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Not applicable Interventional Accepts healthy volunteers

Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD

NCT02498301
Conditions
Travelers' Diarrhea, Functional Bowel Disorders, Reactive Arthritis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years and older
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
5
States / cities
San Diego, California • Honolulu, Hawaii • Marine Corps Base Camp Lejeune, North Carolina + 2 more
Conditions
Hepatic Cirrhosis, Hepatic Encephalopathy (HE)
Interventions
MNK6106, Rifaximin
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Coronado, California • Rialto, California • St. Petersburg, Florida + 1 more
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of Rifaximin in Preventing Campylobacteriosis

NCT02280044
Conditions
Dysentery, Diarrhea, Enteric Campylobacteriosis
Interventions
Rifaximin intervention, Placebo intervention
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Liver Cirrhosis, Hepatic Encephalopathy, Portal Hypertension
Interventions
Rifaximin, Lactulose, Lactulose Placebo, Rifaximin Placebo
Drug
Lead sponsor
Tampa General Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Diarrhea, Gastroenteritis, Bacterial Infection, Acute Diarrhea
Interventions
Rifaximin 200 mg Tablet, Oral Rehydration Therapy (ORT)
Drug · Other
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Lynwood, California • Hialeah, Florida • Miami, Florida + 6 more
Conditions
Papulopustular Rosacea
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
38
States / cities
Yuma, Arizona • Fort Smith, Arkansas • Long Beach, California + 31 more
Conditions
Irritable Bowel Syndrome
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
67
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 61 more
Conditions
Liver Cirrhosis, Chronic Hepatitis C
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
David E. Kaplan, MD MSc
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Small Intestinal Bacterial Overgrowth
Interventions
CapScan collection capsule
Device
Lead sponsor
Envivo Bio Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Mountain View, California
Completed Not applicable Interventional Accepts healthy volunteers

Does Small Intestinal Bacterial Overgrowth Contribute to Functional Dyspepsia

NCT00956397
Conditions
Functional Dyspepsia, Small Intestinal Bacterial Overgrowth, Chronic Abdominal Discomfort
Interventions
Rifaximin, Lactulose Breath Test, Placebo
Drug · Procedure
Lead sponsor
Henry C. Lin, MD
Federal
Eligibility
21 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
HIV-1 Infection
Interventions
Rifaximin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 21 more
Conditions
Hepatic Encephalopathy
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
31
States / cities
Birmingham, Alabama • Aurora, California • Fresno, California + 28 more
Conditions
Diarrhea
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
3
States / cities
South Miami, Florida • Houston, Texas • La Porte, Texas
Terminated Phase 2 Interventional Results available

Rifaximin on Visceral Hypersensitivity

NCT03462966
Conditions
Visceral Hypersensitivity, Irritable Bowel Syndrome
Interventions
Rifaximin
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Diarrhea
Interventions
Rifaximin, Xifaxan®, Placebo Tablet
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Coral Gables, Florida
Conditions
Intestinal FDG Uptake
Interventions
Rifaximin
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Parkinson Disease
Interventions
Rifaximin, Placebo
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
San Francisco, California
Conditions
Non-Constipation Irritable Bowel Syndrome
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
88
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 83 more
Terminated Phase 2 Interventional Results available

Rifaximin in Patients With Diabetic Gastroparesis

NCT04254549
Conditions
Crohn Disease, Diabetic Gastroparesis
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Rosacea
Interventions
Rifaximin (XIFAXAN), Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Francisco, California